Methylprednisolone, valacyclovir, or the combination for vestibular neuritis.
BACKGROUND
Vestibular neuritis is the second most common cause of peripheral vestibular vertigo. Its assumed cause is a reactivation of herpes simplex virus type 1 infection. Therefore, corticosteroids, antiviral agents, or a combination of the two might improve the outcome in patients with vestibular neuritis.


METHODS
We performed a prospective, randomized, double-blind, two-by-two factorial trial in which patients with acute vestibular neuritis were randomly assigned to treatment with placebo, methylprednisolone, valacyclovir, or methylprednisolone plus valacyclovir. Vestibular function was determined by caloric irrigation, with the use of the vestibular paresis formula (to measure the extent of unilateral caloric paresis) within 3 days after the onset of symptoms and 12 months afterward.


RESULTS
Of a total of 141 patients who underwent randomization, 38 received placebo, 35 methylprednisolone, 33 valacyclovir, and 35 methylprednisolone plus valacyclovir. At the onset of symptoms there was no difference among the groups in the severity of vestibular paresis. The mean (+/-SD) improvement in peripheral vestibular function at the 12-month follow-up was 39.6+/-28.1 percentage points in the placebo group, 62.4+/-16.9 percentage points in the methylprednisolone group, 36.0+/-26.7 percentage points in the valacyclovir group, and 59.2+/-24.1 percentage points in the methylprednisolone-plus-valacyclovir group. Analysis of variance showed a significant effect of methylprednisolone (P<0.001) but not of valacyclovir (P=0.43). The combination of methylprednisolone and valacyclovir was not superior to corticosteroid monotherapy.


CONCLUSIONS
Methylprednisolone significantly improves the recovery of peripheral vestibular function in patients with vestibular neuritis, whereas valacyclovir does not.
Department of Neurology, University of Munich, Munich, Germany. mstrupp@nefo.med.uni-muenchen.de
Michael
M
Strupp
Vera Carina
VC
Zingler
Viktor
V
Arbusow
Daniel
D
Niklas
Klaus Peter
KP
Maag
Marianne
M
Dieterich
Sandra
S
Bense
Diethilde
D
Theil
Klaus
K
Jahn
Thomas
T
Brandt
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000998:Antiviral Agents / Q000627:therapeutic use*; D002150:Caloric Tests; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005163:Factor Analysis, Statistical; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D020338:Vestibular Neuronitis / Q000188:drug therapy*
D000998:Antiviral Agents; D005938:Glucocorticoids; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir; D008775:Methylprednisolone